Global Market Study on Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics: Increasing Production of Generic ADHD Drugs to Boost Market Growth


Attention Deficit Hyperactivity Disorder Therapeutics  Market
  • Published On : Apr-2020 |
  • Pages : 177 Pages |
  • Format : Attention Deficit Hyperactivity Disorder Therapeutics  Market Attention Deficit Hyperactivity Disorder Therapeutics  Market Attention Deficit Hyperactivity Disorder Therapeutics  Market Attention Deficit Hyperactivity Disorder Therapeutics  Market

Rising prevalence of ADHD across the globe, owing to the low threshold of diagnostic criteria, is expected to fuel revenue growth of the global attention-deficit hyperactivity disorder (ADHD) therapeutics market over the forecast period. The exact cause for ADHD is still unclear, although genetic influence is observed in most cases. As per data released by the Centers for Disease Control and Prevention (CDC), in 2016, approximately 6.1 million individuals (9.4%), which includes 388,000 children aged 2–5 years, 4 million children aged 6–11 years, and 3 million children aged 12–17 years, were diagnosed with ADHD in the U.S. Besides, boys are more likely to be diagnosed than girls (12.9% as compared to 5.6%) with ADHD. Prevalence of ADHD is rising at an alarming rate, which is expected to fuel revenue growth of global attention-deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder.

Continuous Innovation by ADHD drug manufacturers Anticipated to Accelerate Revenue Growth

Manufacturers are focusing on both, ADHD children and adults. For children, drugs are introduced with various features such as added flavours for easy consumption, while for adults, the focus is on providing a long-lasting effect to avoid the consumption of multiple pills a day. For example, Adzenys (amphetamine)—a fruit-flavoured chewable form pill—is manufactured by Neos Therapeutics for children. It also comes in blister packs rather than a pill bottle, and thus facilitates quick and convenient use. Manufacturers are also focusing on offering products such as stimulants and non-stimulants, comparatively at lower costs. This will lead to the growth of the attention-deficit hyperactivity disorder therapeutics market in untapped regions such as APAC and MEA, which can successfully contribute to overall revenue generation in the global ADHD therapeutics market.

Growth Opportunity in North America and Europe

North America is expected to dominate the global attention-deficit hyperactivity disorder therapeutics market due to growing research & development activities and an increasing number of established players in the ADHD market. Europe is anticipated to be the second-most leading region in the attention-deficit hyperactivity disorder therapeutics market due to the presence of massive pharmaceutical companies in the region. In Europe, Germany will lead the ADHD therapeutics regional market due to the presence of strong distributors and sales channels. Besides, increasing the sales force is also likely to expand product reach across these two regions through distribution & collaboration agreements. These opportunities will lead to market growth of ADHD therapeutics systems in these regions.

Contraindications & Side-effects Associated with ADHD Drugs May Hamper Overall Growth

Despite all the advantages, contraindications and side-effects associated with ADHD drugs are hampering the quality of life of patients, which is expected to hamper revenue growth of the attention-deficit hyperactivity disorder therapeutics market over the forecast period. Contraindications such as allergic reaction to a molecule or any other medicine, medical conditions such as coronary artery disease, bipolar disorder, blood vessel problems, hypertension, kidney disease, seizures, pancytopenia, mydriasis, thrombocytopenic purpura, and visual disturbances, are associated with ADHD drugs.

Side-effects such as hallucinations, fast or irregular heartbeat, severe nausea or vomiting, seizure, impotence, numbness, burning, or tingling, decreased appetite, severe headache, upper abdominal and stomach pain, and weight loss are associated with ADHD drugs. A large number of contraindications and side-effects associated with ADHD drugs is limiting prescriptions based on the medical condition of patients, which is expected to hamper revenue growth.

Competitive Landscape of ADHD Therapeutics Market

The global attention-deficit hyperactivity disorder therapeutics market is a highly fragmented market space, with a huge number of manufacturers present in the market. Key players operating in the attention-deficit hyperactivity disorder therapeutics market across the globe include Pfizer Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, UCB S.A., Hisamitsu Pharmaceutical Co., Inc., and Purdue Pharma L.P., among others. Manufacturers are focusing on mergers, acquisitions, and partnerships to expand their product portfolios and increase revenue in different geographies. For instance, in September 2018, Tris Pharma Inc. acquired NextWave Pharmaceuticals and expanded its ADHD portfolio.

Impact of COVID-19 on ADHD Therapeutics Market

The COVID-19 pandemic is certainly a difficult time for individuals with attention-deficit hyperactivity disorder, owing to their vulnerability to the distress caused by the pandemic and physical distancing measures. As a result of these measures, individuals with ADHD might exhibit increased behavioral problems. On the back of this, ADHD therapeutics will witness significant growth in sales. Furthermore, consumers panic buying essentials as a precautionary measure has resulted in essential medicines going out of stock, thereby driving players to deploy a new batch of medicines. This stands true for ADHD therapeutics as well. The demand for ADHD therapeutics is further surging, as face-to-face sessions and hospital visits of all non-essential medical conditions have been postponed, thus making individuals with ADHD solely reliant on medicines.

Analysts’ Viewpoint

The research report on ADHD therapeutics market provides recommendations, overview of the market, and estimation of market growth over the next decade. Growing prevalence of attention deficit hyperactivity disorder, higher adoption of generic medication, and introduction of new patient-specific ADHD drugs are responsible for the growth of the attention-deficit hyperactivity disorder therapeutics market. North America and Europe hold a substantial share of the global ADHD therapeutics market. Increasing introduction of innovative ADHD therapeutic products such as fruit-flavored chewable pills for children will favor the growth of the global attention-deficit hyperactivity disorder therapeutics market.

Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market - Scope of the Report

Persistence Market Research (PMR) recently published a study on the global attention-deficit hyperactivity disorder (ADHD) therapeutics market. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities restraints, and detailed information about the ADHD therapeutics market structure. The market study presents exclusive information about how the attention-deficit hyperactivity disorder therapeutics market will grow during the forecast period of 2020-2030.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. Other information includes market share analysis by region and by product type, which helps in the deep understanding of the market by researchers, suppliers, manufactures, and distributors. This information can help readers understand the quantitative growth prospects of the attention-deficit hyperactivity disorder therapeutics market during the forecast period.

The study is relevant for manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Business researcher, shareholders, industry experts can leverage the information and data presented in PMR’s study.

The study also includes statistics as well as facts related to macroeconomics factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the attention-deficit hyperactivity disorder therapeutics market. Furthermore, small businesses and new entrants in the ADHD therapeutics market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.

Key Segments of ADHD Therapeutics Market

PMR’s study on the attention-deficit hyperactivity disorder therapeutics market offers information divided into four important segments—drug type, age group, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Type

Age Group

Distribution Channel

Region

  • Stimulants
    • Amphetamine
    • Methylphenidate
    • Dextroamphetamine
    • Dexmethylphenidate
    • Lisdexamfetamine dimesylate
  • Non-stimulants
    • Atomoxetine
    • Bupropion
    • Guanfacine
    • Clonidine
  • Pediatric and Adolescents
  • Adults
  • Hospital Pharmacies
  • Speciality Clinics
  • Retail Pharmacies
  • e-Commerce
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Questions Answered in PMR’s ADHD Therapeutics Market Report

  • Which regions will continue to remain the most profitable regional markets for ADHD therapeutics market players?
  • Which factors will induce a change in the demand for ADHD therapeutics during the assessment period?
  • What are the different opportunities available for emerging players in the attention-deficit hyperactivity disorder therapeutics market?
  • How are supply-side and demand-side drivers impacting the ADHD therapeutics market?
  • How will changing trends impact the attention-deficit hyperactivity disorder therapeutics market?
  • How can market players capture the low-hanging opportunities in the ADHD therapeutics market in developed regions?
  • Which companies are leading the attention-deficit hyperactivity disorder therapeutics market?
  • What are the winning strategies of stakeholders in the ADHD therapeutics market to upscale their position in this landscape?

ADHD Therapeutics Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the attention-deficit hyperactivity disorder therapeutics market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the attention-deficit hyperactivity disorder therapeutics market study include statistics from government healthcare organizations, medicines journals, research journals, press release, annual reports, white papers, directories, and databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the attention-deficit hyperactivity disorder therapeutics market, and makes PMR’s projection on the growth prospects of the ADHD therapeutics market more accurate and reliable.

Companies covered in Attention Deficit Hyperactivity Disorder Therapeutics Market Report

  • Pfizer Inc. 
  • Eli Lilly and Company 
  • Novartis AG 
  • GlaxoSmithKline PLC 
  • Mallinckrodt Pharmaceuticals 
  • Hisamitsu Pharmaceutical Co., Inc. 
  • Johnson & Johnson 
  • UCB S.A. 
  • Purdue Pharma L.P. 

Attention Deficit Hyperactivity Disorder Therapeutics Market

Back To Top